Annual report
7747.TEDINET S100Z3SS
Period2025-07-01 → 2026-06-30
Filed2026-09-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 150
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥145.4bn | 2025-07-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥120.0bn | 2024-07-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥107.5bn | 2023-07-01 → 2024-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥90.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net sales (5-year summary) |
| Revenue | ¥77.7bn | 2021-07-01 → 2022-06-30v | Cons. | Net sales (5-year summary) |
| Operating income | ¥45.2bn | 2025-07-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | ¥30.1bn | 2024-07-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | ¥45.2bn | 2025-07-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥29.6bn | 2024-07-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2023-07-01 → 2024-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.6bn | 2022-07-01 → 2023-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.3bn | 2021-07-01 → 2022-06-30v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥44.7bn | 2025-07-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥18.7bn | 2024-07-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥32.1bn | 2025-07-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.7bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.8bn | 2023-07-01 → 2024-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥13.1bn | 2022-07-01 → 2023-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.9bn | 2021-07-01 → 2022-06-30v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥32.1bn | 2025-07-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | ¥12.8bn | 2024-07-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥218.3bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥193.2bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥191.6bn | at 2024-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥172.6bn | at 2023-06-30v | Cons. | Total assets (5-year summary) |
| Total assets | ¥155.1bn | at 2022-06-30v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥43.9bn | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥41.8bn | at 2025-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥174.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥151.4bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥152.0bn | at 2024-06-30v | Cons. | Net assets |
| Net assets / equity | ¥134.3bn | at 2023-06-30v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥121.1bn | at 2022-06-30v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥64.3bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥54.2bn | at 2025-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥64.3bn | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.2bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥35.7bn | at 2024-06-30v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥34.9bn | at 2023-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥32.3bn | at 2022-06-30v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥40.1bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥40.5bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥34.7bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥19.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥17.3bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥11.7bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥13.4bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥21.2bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥15.1bn | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.7bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥20.0bn | 2025-07-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.1bn | 2024-07-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.9bn | 2023-07-01 → 2024-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.3bn | 2022-07-01 → 2023-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥11.4bn | 2021-07-01 → 2022-06-30v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥120.59 | 2025-07-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.92 | 2024-07-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥58.2 | 2023-07-01 → 2024-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.25 | 2022-07-01 → 2023-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.01 | 2021-07-01 → 2022-06-30v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥40 | 2021-07-01 → 2022-06-30v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥653.57 | at 2026-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥558.31 | at 2025-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥556.71 | at 2024-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥487.12 | at 2023-06-30v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥439.8 | at 2022-06-30v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 79.4% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.9% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.9% | at 2024-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.6% | at 2023-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.0% | at 2022-06-30v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 19.8% | 2025-07-01 → 2026-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2024-07-01 → 2025-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.2% | 2023-07-01 → 2024-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.4% | 2022-07-01 → 2023-06-30v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-07-01 → 2022-06-30v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 10,177 | at 2026-06-30 | Cons. | Number of employees |
| Employees | 9,473 | at 2025-06-30 | Cons. | Number of employees |
| Employees | 9,371 | at 2024-06-30v | Cons. | Number of employees |
| Employees | 10,187 | at 2023-06-30v | Cons. | Number of employees |
| Employees | 10,435 | at 2022-06-30v | Cons. | Number of employees |
| Revenue | ¥99.8bn | 2025-07-01 → 2026-06-30 | Standalone | Net sales |
| Revenue | ¥86.5bn | 2024-07-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥73.8bn | 2023-07-01 → 2024-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥63.7bn | 2022-07-01 → 2023-06-30v | Standalone | Net sales (5-year summary) |
| Revenue | ¥63.5bn | 2021-07-01 → 2022-06-30v | Standalone | Net sales (5-year summary) |
| Operating income | ¥31.8bn | 2025-07-01 → 2026-06-30 | Standalone | Operating income |
| Operating income | ¥21.5bn | 2024-07-01 → 2025-06-30 | Standalone | Operating income |
| Ordinary income | ¥36.0bn | 2025-07-01 → 2026-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥36.7bn | 2024-07-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥13.9bn | 2023-07-01 → 2024-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.3bn | 2022-07-01 → 2023-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.2bn | 2021-07-01 → 2022-06-30v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥35.5bn | 2025-07-01 → 2026-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥28.4bn | 2024-07-01 → 2025-06-30 | Standalone | Income before income taxes |
| Net income | ¥26.8bn | 2025-07-01 → 2026-06-30 | Standalone | Profit loss |
| Net income | ¥21.7bn | 2024-07-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | ¥10.9bn | 2023-07-01 → 2024-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥7.2bn | 2022-07-01 → 2023-06-30v | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.5bn | 2021-07-01 → 2022-06-30v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥175.7bn | at 2026-06-30 | Standalone | Assets |
| Total assets | ¥155.3bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥139.1bn | at 2024-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥127.3bn | at 2023-06-30v | Standalone | Total assets (5-year summary) |
| Total assets | ¥120.9bn | at 2022-06-30v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥56.7bn | at 2026-06-30 | Standalone | Liabilities |
| Total liabilities | ¥46.5bn | at 2025-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥119.0bn | at 2026-06-30 | Standalone | Net assets |
| Net assets / equity | ¥108.8bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥97.8bn | at 2024-06-30v | Standalone | Net assets |
| Net assets / equity | ¥90.2bn | at 2023-06-30v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥86.2bn | at 2022-06-30v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥49.9bn | at 2026-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥37.2bn | at 2025-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥100.74 | 2025-07-01 → 2026-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥79.79 | 2024-07-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.11 | 2023-07-01 → 2024-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.61 | 2022-07-01 → 2023-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.09 | 2021-07-01 → 2022-06-30v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥35.08 | 2021-07-01 → 2022-06-30v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥48.24 | 2025-07-01 → 2026-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24.23 | 2024-07-01 → 2025-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20.37 | 2023-07-01 → 2024-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14.48 | 2022-07-01 → 2023-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11.99 | 2021-07-01 → 2022-06-30v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥448.39 | at 2026-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥403.61 | at 2025-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥360.2 | at 2024-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥332.15 | at 2023-06-30v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥317.39 | at 2022-06-30v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 67.7% | at 2026-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.1% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.3% | at 2024-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.9% | at 2023-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2022-06-30v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 23.5% | 2025-07-01 → 2026-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 21.0% | 2024-07-01 → 2025-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.6% | 2023-07-01 → 2024-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-07-01 → 2023-06-30v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2021-07-01 → 2022-06-30v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 265,332,300 | at 2026-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2024-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2023-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2022-06-30v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,285 | at 2026-06-30 | Standalone | Number of employees |
| Employees | 1,196 | at 2025-06-30 | Standalone | Number of employees |
| Employees | 1,088 | at 2024-06-30v | Standalone | Number of employees |
| Employees | 1,016 | at 2023-06-30v | Standalone | Number of employees |
| Employees | 1,041 | at 2022-06-30v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-07-01 → 2026-06-30 | ¥869m |
| Reconciling Itemsreconciling | depreciation | 2025-07-01 → 2026-06-30 | ¥584m |
| Reconciling Itemsreconciling | revenue | 2025-07-01 → 2026-06-30 | −¥16.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-07-01 → 2026-06-30 | −¥16.8bn |
| Reconciling Itemsreconciling | segment assets | at 2026-06-30 | ¥35.4bn |
| Reconciling Itemsreconciling | segment profit | 2025-07-01 → 2026-06-30 | −¥9.5bn |
| Devicereportable segment | capex | 2025-07-01 → 2026-06-30 | ¥3.4bn |
| Devicereportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥3.5bn |
| Devicereportable segment | employees | at 2026-06-30 | 3904 pure |
| Devicereportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥35.4bn |
| Devicereportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥18.6bn |
| Devicereportable segment | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥16.8bn |
| Devicereportable segment | segment assets | at 2026-06-30 | ¥55.8bn |
| Devicereportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥8.5bn |
| Medicalreportable segment | capex | 2025-07-01 → 2026-06-30 | ¥5.4bn |
| Medicalreportable segment | depreciation | 2025-07-01 → 2026-06-30 | ¥4.7bn |
| Medicalreportable segment | employees | at 2026-06-30 | 5781 pure |
| Medicalreportable segment | revenue | 2025-07-01 → 2026-06-30 | ¥126.8bn |
| Medicalreportable segment | revenue external | 2025-07-01 → 2026-06-30 | ¥126.8bn |
| Medicalreportable segment | segment assets | at 2026-06-30 | ¥127.1bn |
| Medicalreportable segment | segment profit | 2025-07-01 → 2026-06-30 | ¥46.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-07-01 → 2026-06-30 | ¥8.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-07-01 → 2026-06-30 | ¥8.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-07-01 → 2026-06-30 | ¥162.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-07-01 → 2026-06-30 | ¥145.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-07-01 → 2026-06-30 | ¥16.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-06-30 | ¥182.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-07-01 → 2026-06-30 | ¥54.7bn |
| Reconciling Itemsreconciling | capex | 2024-07-01 → 2025-06-30 | ¥1.3bn |
| Reconciling Itemsreconciling | depreciation | 2024-07-01 → 2025-06-30 | ¥572m |
| Reconciling Itemsreconciling | revenue | 2024-07-01 → 2025-06-30 | −¥14.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-07-01 → 2025-06-30 | −¥14.2bn |
| Reconciling Itemsreconciling | segment assets | at 2025-06-30 | ¥30.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-07-01 → 2025-06-30 | −¥8.0bn |
| Devicereportable segment | capex | 2024-07-01 → 2025-06-30 | ¥4.2bn |
| Devicereportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥3.4bn |
| Devicereportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥26.4bn |
| Devicereportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥12.2bn |
| Devicereportable segment | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥14.2bn |
| Devicereportable segment | segment assets | at 2025-06-30 | ¥49.6bn |
| Devicereportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥4.6bn |
| Medicalreportable segment | capex | 2024-07-01 → 2025-06-30 | ¥2.9bn |
| Medicalreportable segment | depreciation | 2024-07-01 → 2025-06-30 | ¥5.2bn |
| Medicalreportable segment | revenue | 2024-07-01 → 2025-06-30 | ¥107.8bn |
| Medicalreportable segment | revenue external | 2024-07-01 → 2025-06-30 | ¥107.8bn |
| Medicalreportable segment | segment assets | at 2025-06-30 | ¥113.1bn |
| Medicalreportable segment | segment profit | 2024-07-01 → 2025-06-30 | ¥33.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-07-01 → 2025-06-30 | ¥7.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-07-01 → 2025-06-30 | ¥8.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-07-01 → 2025-06-30 | ¥134.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-07-01 → 2025-06-30 | ¥120.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-07-01 → 2025-06-30 | ¥14.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-06-30 | ¥162.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-07-01 → 2025-06-30 | ¥38.1bn |
| Devicereportable segment | employees | at 2026-06-30 | 365 pure |
| Medicalreportable segment | employees | at 2026-06-30 | 774 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,717
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | CurrentYearDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -5182000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -2381000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -4446000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -10553000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -5533000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -6534000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -446000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -502000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -8107000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -19971000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | -1459000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 2226000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 17542000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 10610000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 35658000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 53200000000 | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | Prior1YearDuration | － | JPY |
| Increase decrease in cash and cash equivalents resulting from change of scope of consolidation cce | CurrentYearDuration | 452000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 53200000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 64264000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 20 | |
| Notes receivable trade | Prior1YearInstant | 136000000 | JPY |
| Notes receivable trade | CurrentYearInstant | 31000000 | JPY |
| Accounts receivable trade | Prior1YearInstant | 15630000000 | JPY |
| Accounts receivable trade | CurrentYearInstant | 18890000000 | JPY |
| Write downs of inventories | Prior1YearDuration | 152000000 | JPY |
| Write downs of inventories | CurrentYearDuration | -377000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 12248000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 13372000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02349-000MedicalReportableSegmentsMember | 107779000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02349-000DeviceReportableSegmentsMember | 12245000000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 120025000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 120025000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02349-000MedicalReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02349-000DeviceReportableSegmentsMember | 14151000000 | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 14151000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -14151000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02349-000MedicalReportableSegmentsMember | 107779000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02349-000DeviceReportableSegmentsMember | 26396000000 | JPY |
| Net sales | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 134176000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -14151000000 | JPY |
| Net sales | Prior1YearDuration | 120025000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02349-000MedicalReportableSegmentsMember | 33445000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02349-000DeviceReportableSegmentsMember | 4624000000 | JPY |
| Operating income | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 38069000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -7990000000 | JPY |
| Operating income | Prior1YearDuration | 30079000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |